BAC
Bank of America Corporation
BAC has a slight edge over MRSH overall, supported by stronger fundamentals and stronger modeled upside.
MRSH
Marsh & McLennan Companies, Inc.
MRSH offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
MRSH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
MRSH's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like MRSH.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
MRSH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $206 | — |
| Cheap | 24x | $197 | -4.3% |
| Current | 25x | $206 | — |
| Fair | 27x | $229 | +12% |
| Expensive | 30x | $254 | +23% |
Historical ranges are pointers, not guarantees.
MRSH has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
MRSH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for MRSH, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over MRSH on earnings, with more consistent year-over-year improvement.
MRSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.25 | +35% |
| Q3 2026 | $8.36 | +0.4% |
| Q2 2026 | $8.18 | -1.8% |
| Q1 2026 | $8.00 | -1.8% |
| Q4 2025 | $8.43 | +3.1% |
| Q3 2025 | $8.33 | +2.6% |
| Q2 2025 | $8.33 | +3.1% |
| Q1 2025 | $8.15 | +3.4% |
| Q4 2024 | $8.18 | +8.6% |
MRSH earned $8.36 per share over the past year, about the same as the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over MRSH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over MRSH on profitability, with a higher operating margin.
MRSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.9B | +8.1% |
| Q2 2026 | $7.4B | +6.2% |
| Q1 2026 | $7.6B | +7.6% |
| Q4 2025 | $6.6B | +8.7% |
| Q3 2025 | $6.4B | +11% |
| Q2 2025 | $7B | +12% |
| Q1 2025 | $7.1B | +9.1% |
| Q4 2024 | $6.1B | +9.2% |
MRSH's revenue has grown year over year for 15 quarters in a row: $6.9B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | -0.7 points |
| Q2 2026 | 26% | -0.6 points |
| Q1 2026 | 23% | -5.3 points |
| Q4 2025 | 18% | -0.3 points |
| Q3 2025 | 18% | -1 points |
| Q2 2025 | 26% | -0.2 points |
| Q1 2025 | 28% | -1.3 points |
| Q4 2024 | 19% | -1 points |
MRSH's operating margin was 18% last quarter, down 0.7 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
MRSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.4B | -30% |
| Q2 2026 | $1.5B | -10% |
| Q1 2026 | -$750M | -$73M |
| Q4 2025 | $2.1B | +9.4% |
| Q3 2025 | $2B | +9.3% |
| Q2 2025 | $1.6B | +42% |
| Q1 2025 | -$677M | +$191M |
| Q4 2024 | $1.9B | +13% |
MRSH has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over MRSH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
MRSH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -3M shares |
| 1 year | -3% | -15M shares |
| 3 years | -4% | -20M shares |
| 5 years | -6.6% | -34M shares |
| Available history | -6.3% | -32M shares |
MRSH has 479M diluted shares, down 3% from a year ago, with $3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $504M |
| Q2 2026 | $757M |
| Q1 2026 | $755M |
| Q4 2025 | $1B |
| Q3 2025 | $402M |
| Q2 2025 | $300M |
| Q1 2025 | $300M |
| Q4 2024 | — |
MRSH spent $3B buying back its own shares over the past year, about three times what it spent the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
MRSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.9x | Moderate |
| Q2 2026 | 3.0x | Moderate |
| Q1 2026 | 3.0x | Elevated |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 2.9x | Moderate |
| Q4 2024 | 2.7x | Moderate |
MRSH has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
MRSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.6 | Neutral |
| Stochastic | 85.8 | Overbought |
MRSH's weekly RSI is 67 (neutral) and its Stochastic is 86 (overbought).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over MRSH on valuation relative to its sector.
MRSH PE vs Financial Services Sector
| Metric | MRSH | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 13x | 89% above |
| PE % | 22 | 63 | 41 pts below |
MRSH is trading at 25x earnings, a 89% premium to the Financial Services sector's median of 13x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
MRSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $189.2 | 8.7% above |
| 20 week MA | $186.3 | 10% above |
| 50 week MA | $179.6 | 15% above |
| 100 week MA | $196.4 | 4.7% above |
| 200 week MA | $197.1 | 4.4% above |
MRSH has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
MRSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $112.0 | $115.1 | +2.8% |
| 2021 | $115.1 | $170.6 | +48% |
| 2022 | $170.6 | $165.6 | -2.9% |
| 2023 | $165.6 | $189.5 | +14% |
| 2024 | $189.5 | $213.5 | +13% |
| 2025 | $213.5 | $187.0 | -12% |
| 2026 YTD | $187.0 | $205.7 | +10% |
MRSH has the edge over BAC on returns for 2026, with the stronger performance.